Compare PKST & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKST | ADCT |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 574.7M | 484.4M |
| IPO Year | 2014 | 2019 |
| Metric | PKST | ADCT |
|---|---|---|
| Price | $20.86 | $4.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $21.00 | $7.60 |
| AVG Volume (30 Days) | ★ 1.1M | 729.3K |
| Earning Date | 05-22-2026 | 03-27-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ 44.90 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,981,000.00 | $70,837,000.00 |
| Revenue This Year | N/A | $13.66 |
| Revenue Next Year | N/A | $2.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.84 |
| 52 Week Low | $10.35 | $1.05 |
| 52 Week High | $20.97 | $4.80 |
| Indicator | PKST | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 87.96 | 62.60 |
| Support Level | $20.70 | $4.00 |
| Resistance Level | $20.97 | $4.26 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 45.00 | 95.56 |
Peakstone Realty Trust is an internally managed, publicly registered real estate investment trust (REIT) that owns and operates predominately single-tenant industrial and office properties with creditworthy tenants and long-term leases. Peakstone's portfolio consists of newer vintage, and well-located real estate assets in majorly high-growth coastal and sunbelt markets. The company has two reportable segments: Industrial and Office. The Industrial segment consists of industrial outdoor storage properties which have a low building-to-land ratio, or low coverage, maximizing yard space for the display, movement, and storage of materials and equipment. The Office segment includes office, R&D and data center properties.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).